Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Manal F. Abdelmalek"'
Autor:
Raluca Pais, Bertrand Cariou, Mazen Noureddin, Sven Francque, Jörn M. Schattenberg, Manal F. Abdelmalek, Gadi Lalazar, Sharat Varma, Julie Dietrich, Veronica Miller, Arun Sanyal, Vlad Ratziu
Publikováno v:
Journal of Hepatology.
Autor:
Manal F. Abdelmalek, Jeongeun Hyun, Steven R. Patierno, Rebecca Caffrey, Cynthia A. Moylan, Muthana Al Abo, Anna Mae Diehl, Xiyou Zhou, Seh-Hoon Oh, Arun J. Sanyal, Kun Xiang, Rajesh Kumar Dutta, Raquel Maeso-Díaz, Jennifer A. Freedman
Publikováno v:
J Hepatol
Background & Aims Non-alcoholic fatty liver disease (NAFLD), the hepatic correlate of the metabolic syndrome, is a major risk factor for hepatobiliary cancer (HBC). Although chronic inflammation is thought to be the root cause of all these diseases,
Autor:
Sven Francque, Manal F. Abdelmalek, Veronica Miller, Claudia Filozof, Elmer Schabel, Katherine Barradas, Mazen Noureddin, Mark Berner-Hansen, Jörn M. Schattenberg, Stephanie O Omokaro, Oliver Glass
Publikováno v:
Journal of hepatology
Lifestyle modification is the foundation of treatment recommendations for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The design of clinical trials in NASH may be impeded by the lack of a systematic approach to
Autor:
Guadalupe Garcia-Tsao, Jaime Bosch, Zeid Kayali, Stephen A. Harrison, Manal F. Abdelmalek, Eric Lawitz, Sanjaya K. Satapathy, Marwan Ghabril, Mitchell L. Shiffman, Ziad H. Younes, Paul J. Thuluvath, Annalisa Berzigotti, Agustin Albillos, James M. Robinson, David T. Hagerty, Jean L. Chan, Arun J. Sanyal, M. Abdelmalek, K. Bhamidimarri, B. Borg, S. Caldwell, J. Fenkel, B. Freilich, M. Fuchs, M. Ghabril, R. Ghalib, S. Gonzalez, S. Gordon, B. Hameed, S. Harrison, Z. Kayali, N. Kemmer, K. Korenblat, M. Lai, C. Landis, E. Lawitz, W. Lee, S. Lidofsky, E. Mena, M. Noureddin, A. Paredes, N. Pyrsopoulos, R. Reddy, M. Rinella, D. Rockey, M. Rodriguez, M. Ryan, S. Sarkar, S. Satapathy, A. Scanga, M. Shiffman, M. Siddiqui, D. Simonetto, W. Syn, P. Thuluvath, R. Vemulapalli, J. Vierling, Z. Younes, A. Albillos, J. Arenas Ruiz-Tapiador, S. Augustin, J. Calleja, J. Crespo Garcia, L. Garcia Buey, J.C. Garcia-Pagan, C. Villanueva, C. Bureau, N. Carbonell, V. Leroy, P.-E. Rautou, H. Heinzow, I. Schiefke, A. Zipprich, A. Berzigotti, B. Muellhaupt
Publikováno v:
Garcia-Tsao, Guadalupe; Bosch, Jaime; Kayali, Zeid; Harrison, Stephen A; Abdelmalek, Manal F; Lawitz, Eric; Satapathy, Sanjaya K; Ghabril, Marwan; Shiffman, Mitchell L; Younes, Ziad H; Thuluvath, Paul J; Berzigotti, Annalisa; Albillos, Agustin; Robinson, James M; Hagerty, David T; Chan, Jean L; Sanyal, Arun J (2020). Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension. Journal of hepatology, 72(5), pp. 885-895. Elsevier 10.1016/j.jhep.2019.12.010
Background & Aims Emricasan, an oral pan-caspase inhibitor, decreased portal pressure in experimental cirrhosis and in an open-label study in patients with cirrhosis and severe portal hypertension, defined as a hepatic venous pressure gradient (HVPG)
Autor:
Manal F. Abdelmalek, Lei Ling, Guy Neff, Naim Alkhouri, Charles Chen, Alex DePaoli, Hsiao Lieu, Diana Leeming, Morten Karsdal, Stephen Harrison
Publikováno v:
Journal of Hepatology. 77:S495
Autor:
Rohit Loomba, Manal F. Abdelmalek, Matthew Armstrong, Maximilian Jara, Mette Kjaer, Niels Krarup, Eric Lawitz, Vlad Ratziu, Arun Sanyal, Jörn Schattenberg, Philip N. Newsome
Publikováno v:
Journal of Hepatology. 77:S10
Autor:
Manal F. Abdelmalek, Margery A. Connelly, Stephen J. Rossi, Mary E. Rinella, Angelo H. Paredes, Stephen A. Harrison, Lei Ling, James F. Trotter, Mark J. Jaros, Alex M. DePaoli
Publikováno v:
Journal of Hepatology. 70:735-744
NGM282, an engineered analogue of the gut hormone FGF19, improves hepatic steatosis and fibrosis biomarkers in patients with non-alcoholic steatohepatitis (NASH). However, NGM282 increases serum cholesterol levels by inhibiting CYP7A1, which encodes
Autor:
Anna Mae Diehl, Nezam H. Afdhal, Andrew J. Muir, Jaime Bosch, G. Mani Subramanian, Zachary Goodman, Raul Aguilar Schall, Arun J. Sanyal, Stephen A. Harrison, Stephen H. Caldwell, B. Mccolgan, Maria Stepanova, Manal F. Abdelmalek, Robert P. Myers, Vlad Ratziu, Zobair M. Younossi, Mitchell L. Shiffman
Publikováno v:
Journal of Hepatology. 69:1365-1370
Although patients with cryptogenic cirrhosis have historically been considered as having "burnt-out" non-alcoholic steatohepatitis (NASH), some controversy remains. The aim of this study was to compare outcomes of patients with cryptogenic cirrhosis
Autor:
Fernando Membreno, Giuseppe Morelli, Ray Thomason, Kalyan Ram Bhamidimarri, Dawn Torres, Andrew Scanga, Danielle Brandman, Guy W. Neff, Mark McKenzie, Stephen H. Caldwell, Kathleen E. Corey, Nadeem Anwar, Kimberly A. Brown, James Strobel, Sammy Saab, Thomas Amankonah, Bal R. Bhandari, Souvik Sarkar, Don C. Rockey, Miguel Á. Rodríguez, Mazen Noureddin, Edward Mena, Nikolaos Pyrsopoulos, Ayman Koteish, Gary A. Abrams, Andrew DeLemos, Richard Frederick, Bhaktasharan Patel, David T. Hagerty, Amy Stratton, Kathryn J. Lucas, Ethan M. Weinberg, Zeid Kayali, Anita Kohli, Marina Roytman, Kris V. Kowdley, Nicole Wedick, Brett E. Fortune, Michael P. Curry, Sofia Jakab, Kiran Bambha, Satinder Gill, Stevan A. Gonzalez, Nikunj Shah, Warren N. Schmidt, Jean L. Chan, Charles S. Landis, Bradley Freilich, Catherine Frenette, Hugo E. Vargas, Mary E. Rinella, Mohammad S. Siddiqui, Andrew P. Keaveny, George Therapondos, Elizabeth C. Verna, Ray Kim, James M. Robinson, David I. Bernstein, Marwan Ghabril, Reem Ghalib, John M. Vierling, Manal F. Abdelmalek, Paul J. Thuluvath, Jen-Jung Pan, Ravi Ravendhran, Amanda Wieland, Eric Lawitz, Justin Reynolds, Victor Ankoma-Sey, Mitchell L. Shiffman, Nyingi Kemmer, William M. Lee, Viviana Figueroa-Diaz, Douglas A. Simonetto, Jonathan Huang, Aasim Sheikh, Parvez S. Mantry, Harvey Tatum, Lance Stein
Publikováno v:
Journal of hepatology. 74(2)
Background & Aims Non-alcoholic steatohepatitis is a leading cause of end-stage liver disease. Hepatic steatosis and lipotoxicity cause chronic necroinflammation and direct hepatocellular injury resulting in cirrhosis, end-stage liver disease and hep
Publikováno v:
Journal of Hepatology. 70:e782-e783